NCT02007005 - Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

February 29, 2012

Study Completion Date

September 30, 2013

Conditions

Superficial Bladder Cancer

Interventions

DRUG

abnobaVISCUM Fraxini

intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs

Trial Locations (2)

Theodor Bilharz Research Institute, Giza

Clinic of Urology of the University Hospital of Essen, Essen